FDA
-
-
-
-
-
-
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
-
-
-
-
-
-
FDA approves Novo Nordisk's higher-dose Wegovy injection for weight loss
-
-
-
-
-
-
-
HIMS partners with Novo Nordisk, shifts US weight loss strategy
-
-
-
-
-
-
-
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
-
-
-
-
-
-
-
FDA moves to restrict copycat GLP-1 weight loss drugs
-
-
-
-
-
-
-
Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly
-
-
-
-
-
-
-
Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill
-
328,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

